Suppr超能文献

亚太地区造血干细胞移植的进展:APBMT 2005-2015 年的第二次报告。

Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005-2015.

机构信息

Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan.

St. Vincent's Pathology, St. Vincent's Health Network Sydney, Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia.

出版信息

Bone Marrow Transplant. 2019 Dec;54(12):1973-1986. doi: 10.1038/s41409-019-0554-9. Epub 2019 May 14.

Abstract

Between 2005 and 2015, 138,165 hematopoietic stem cell transplantation (HSCT) were reported in 18 countries/regions in the Asia-Pacific region. In this report, we describe current trends in HSCT throughout the Asia-Pacific region and differences among nations in this region and various global registries. Since 2008, more than 10,000 HSCTs have been recorded each year by the Asia-Pacific Blood and Marrow Transplantation Group Data Center. Between 2005 and 2015, the greatest increase in the number of HSCTs was observed in Vietnam. Allogeneic HSCT was performed more frequently than autologous HSCT, and a majority of cases involved related donors. Regarding allogeneic HSCT, the use of cord blood has remained steady, especially in Japan, and the number of cases involving related HLA non-identical donors has increased rapidly, particularly in China. The incidence of hemoglobinopathy, a main indication for allogeneic HSCT in India, China, Iran, and Pakistan, increased nearly six-fold over the last decade. Among the 18 participating countries/regions, the transplant rate per population varied widely according to the absolute number of HSCTs and the national/regional population size. We believe that this report will not only benefit the AP region but will also provide information about HSCT to other regions worldwide.

摘要

在 2005 年至 2015 年间,亚太地区的 18 个国家/地区报告了 138165 例造血干细胞移植(HSCT)。在本报告中,我们描述了整个亚太地区 HSCT 的当前趋势,以及该地区各国之间以及与全球各登记处之间的差异。自 2008 年以来,亚太血液和骨髓移植组数据中心每年记录的 HSCT 超过 10000 例。在 2005 年至 2015 年间,HSCT 数量的增长最大的是越南。异基因 HSCT 比自体 HSCT 更频繁地进行,并且大多数病例涉及相关供体。关于异基因 HSCT,脐带血的使用保持稳定,尤其是在日本,涉及相关 HLA 非匹配供体的病例数量迅速增加,尤其是在中国。过去十年中,印度、中国、伊朗和巴基斯坦等国导致需要进行异基因 HSCT 的血红蛋白病的发病率增加了近六倍。在参与的 18 个国家/地区中,根据 HSCT 的绝对数量和国家/地区人口规模,每人口的移植率差异很大。我们相信,本报告不仅将使亚太地区受益,还将为全球其他地区提供有关 HSCT 的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/877d/9763097/5376ee04c3b8/41409_2019_554_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验